BackgroundCheck.run
Search For

Aditya Ranjan Das, 59325 Bluefish Ct, San Mateo, CA 94404

Known as:
Aditya R Das Ashidhara Das Adty Das I Das

Aditya Das Phones & Addresses

325 Bluefish Ct, Foster City, CA 94404    650-3451690    650-3459918   

1033 Shell Blvd, Foster City, CA 94404    650-3451690    650-3459918   

611 Bounty Dr, Foster City, CA 94404    650-3459918   

San Mateo, CA   

Morgantown, WV   

San Diego, CA   

La Jolla, CA   

Work

Company: Pharmaceutical consulting llc Feb 2004 Position: Founder and principal

Education

School / High School: University of California Irvine- Irvine, CA Aug 2003 Specialities: MBA
Get Report
Control this profile

Mentions for Aditya Ranjan Das

Aditya Das resumes & CV records

Resumes

Aditya Das Photo 40

Founder And Principal

Location:
325 Bluefish Ct, Foster City, CA 94404
Industry:
Pharmaceuticals
Work:
Stanford University School of Medicine
Advisor Aaipharma Services Corp. Aug 2007 - Jan 2010
Director, Business Development Cardinal Health Aug 2006 - Jul 2007
Account Manager, Business Development Mds Pharma Services Jun 2004 - Jul 2006
Director, Business Development Pharmaceutical Consulting Jun 2004 - Jul 2006
Founder and Principal Alexza Pharmaceuticals Feb 2003 - Jun 2004
Senior Scientist Nektar Therapeutics 1999 - 2002
Research Scientist Valentis Jan 1998 - Jan 1999
Scientist-Ii Chugai Biopharmaceuticals Aug 1993 - Dec 1997
Research Scientist
Education:
Product Quality Research Institute Dec 2006
University of Wisconsin Symposium Apr 2005
Uc Irvine Aug 2003
Master of Business Administration, Masters University of California, Irvine - the Paul Merage School of Business 2001 - 2003
Master of Business Administration, Masters Uc Irvine 2003
Pharmaceutical Training Institute Nov 2001
Pharmaceutical Training Institute Oct 2001
Massachusetts Institute of Technology Jun 2000
University of Wisconsin May 2000
West Virginia University 1989 - 1993
Doctorates, Doctor of Philosophy, Chemical Engineering Carnegie Mellon University 1987 - May 1989
Master of Science, Masters, Chemical Engineering University of New Hampshire 1984 - May 1987
Bachelors, Bachelor of Science, Chemical Engineering American Institute 1987
American Institute of Chemical Engineers Annual 1985
St Xavier's College, Bombay 1981 - 1983
Cathedral and John Connon School, Bombay 1974 - 1981
Skills:
Drug Development, Biotechnology, Biopharmaceuticals, Life Sciences, Gmp, Clinical Development, Pharmaceutical Industry, Lifesciences, Validation, Clinical Trials, Analytical Chemistry, Technology Transfer, Pharmaceutics, Assay Development, Protein Chemistry, Drug Delivery, Pharmacology, Ctd, Ind, Medical Devices, In Vitro, Nda
Interests:
Career
Electronics
Home Improvement
Reading
Donor
Home Decoration
Languages:
English
Bengali
Hindi
Aditya Das Photo 41

Director Business Development

Location:
San Francisco, CA
Industry:
Pharmaceuticals
Work:
Mds Pharma Services
Director Business Development
Aditya Das Photo 42

Aditya Das

Aditya Das Photo 43

Aditya Das - Foster City, CA

Work:
Pharmaceutical Consulting LLC Feb 2004 to 2000
Founder and Principal XenoTech LLC - Foster City, CA Nov 2011 to Jan 2013
Director Global Business Development and Strategy Pharmaceutical Consulting LLC 2012 to 2012 XenoTech LLC - Foster City, CA Oct 2010 to Nov 2011
Account Manager AAI Pharma Inc - Foster City, CA Jul 2007 to Jan 2010
Director, Business Development Cardinal Health - Foster City, CA Jul 2006 to Jul 2007
Account Manager, Business Development MDS Pharma Services - Foster City, CA Jun 2004 to Jul 2006
Director, Business Development Alexza MDC - Palo Alto, CA Jan 2003 to Jun 2004
Senior Scientist Inhale Therapeutic Systems - San Carlos, CA Nov 1999 to Dec 2002
Scientist II Oread Incorporated - Palo Alto, CA Jan 1999 to Aug 1999
Scientist II Megabios Corporation - Burlingame, CA Jan 1998 to Jan 1999
Scientist Chugai Biopharmaceuticals Inc - San Diego, CA Aug 1993 to Dec 1997
Research Scientist West Virginia University - Morgantown, WV Aug 1989 to Aug 1993
Research Assistant Carnegie Mellon University - Pittsburgh, PA Aug 1987 to May 1989
Research Assistant
Education:
University of California Irvine - Irvine, CA Aug 2003
MBA West Virginia University and National Institute - Morgantown, WV Aug 1993
Ph.D. in Chemical Engineering Carnegie Mellon University - Pittsburgh, PA May 1989
M.S. in Chemical Engineering University of New Hampshire - Durham, NH May 1987
B.S. in Chemical Engineering

Publications & IP owners

Us Patents

Ibuprofen Solid Oral Dosage Composition Comprising A Methacrylic Acid Copolymer

US Patent:
2013026, Oct 3, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/836661
Inventors:
ADITYA R. DAS - Foster City CA, US
Assignee:
TEIKOKU PHARMA USA, INC. - San Jose CA
International Classification:
A61K 9/00
US Classification:
514570
Abstract:
Aspects of the invention include organoleptically acceptable solid oral dosage compositions of ibuprofen. Solid oral dosage compositions according to certain embodiments include ibuprofen and a methacrylic acid copolymer in an amount sufficient to make the composition organoleptically acceptable for administering in an oral cavity of a subject to deliver ibuprofen to the subject. Methods for preparing and using solid oral dosage compositions of the invention are also described.

Respiratory Tract Delivery Of Levodopa And Dopa Decarboxylase Inhibitor For Treatment Of Parkinson's Disease

US Patent:
2022023, Jul 28, 2022
Filed:
Feb 28, 2022
Appl. No.:
17/682033
Inventors:
- Seattle WA, US
Kelsey H. Satterly - Seattle WA, US
Inna Dashevsky - Seattle WA, US
Aditya R. Das - Foster City CA, US
Stephen B. Shrewsbury - Fallbrook CA, US
Gregory J. Davies - Issaquah WA, US
Bhavin Y. Gajera - Bellevue WA, US
International Classification:
A61K 31/198
A61P 25/16
A61K 9/00
Abstract:
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Intranasal Delivery Of Olanzapine By Precision Olfactory Device

US Patent:
2022018, Jun 16, 2022
Filed:
Jan 12, 2022
Appl. No.:
17/574511
Inventors:
- Seattle WA, US
Kelsey H. Satterly - Seattle WA, US
Inna Dashevsky - Seattle WA, US
Aditya R. Das - Foster City CA, US
International Classification:
A61K 9/00
A61K 31/5513
A61M 15/00
A61K 9/16
A61P 25/18
A61K 31/00
Abstract:
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Respiratory Tract Delivery Of Levodopa And Dopa Decarboxylase Inhibitor For Treatment Of Parkinson's Disease

US Patent:
2020004, Feb 13, 2020
Filed:
Jul 19, 2019
Appl. No.:
16/517423
Inventors:
- Seattle WA, US
Kelsey H. Satterly - Seattle WA, US
Inna Dashevsky - Seattle WA, US
Aditya R. Das - Foster City CA, US
Stephen B. Shrewsbury - Fallbrook CA, US
Gregory J. Davies - Issaquah WA, US
Bhavin Y. Gajera - Bellevue WA, US
International Classification:
A61K 31/198
A61K 9/00
A61P 25/16
Abstract:
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Intranasal Delivery Of Olanzapine By Precision Olfactory Device

US Patent:
2019024, Aug 8, 2019
Filed:
Jan 4, 2019
Appl. No.:
16/240653
Inventors:
- Seattle WA, US
Kelsey H. Satterly - Seattle WA, US
Inna Dashevsky - Seattle WA, US
Aditya R. Das - Foster City CA, US
International Classification:
A61K 9/00
A61K 31/5513
A61K 9/16
A61M 15/00
Abstract:
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Possible Relatives

Debashis Das  Debashish Das  Debasish Das  Debjani Das  Deepak K Das  Deepti Das  Dilip K Das  Aditya M Patel  Aditya V Chauhan  Aditya M Sharma 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.